Old Web
English
Sign In
Acemap
>
authorDetail
>
Arto Kokko
Arto Kokko
Rheumatoid arthritis
Medicine
Internal medicine
Physical therapy
Rheumatology
5
Papers
150
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care
2019
Clinical and Experimental Rheumatology
Elena Nikiphorou
Pekka Hannonen
J. Asikainen
Jelena Borodina
Arto Kokko
Kirsi Paalanen
T. Rannio
Tuulikki Sokka
Show All
Source
Cite
Save
Citations (5)
Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis
2016
The Journal of Rheumatology
T. Rannio
J. Asikainen
Arto Kokko
Pekka Hannonen
Tuulikki Sokka
Show All
Source
Cite
Save
Citations (15)
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.
2015
Expert Opinion on Biological Therapy
Elena Nikiphorou
Hannu Kautiainen
Pekka Hannonen
J. Asikainen
Arto Kokko
T. Rannio
Tuulikki Sokka
Show All
Source
Cite
Save
Citations (95)
Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics.
2013
Clinical and Experimental Rheumatology
Tuulikki Sokka
Glenn Haugeberg
J. Asikainen
Widding Hansen Ij
Arto Kokko
T. Rannio
D.M. Soldal
Pekka Hannonen
Show All
Source
Cite
Save
Citations (35)
FRI0095 Similar clinical outcomes in rheumatoid arthritis with more vs. Less expensive treatment strategies. Results from two rheumatology clinics with standard monitoring of all patients
2013
Annals of the Rheumatic Diseases
Tuulikki Sokka
G. Haugeberg
J. Asikainen
I.J. Widding Hansen
Arto Kokko
T. Rannio
D.M. Soldal
Pekka Hannonen
Show All
Source
Cite
Save
Citations (0)
1